Fibrocell Science (FCSC) Posts Q1 Loss of 35c/Share

Fibrocell Science (NYSE: FCSC) reported Q1 EPS of ($0.35), $0.20 worse than the analyst estimate of ($0.15).

“2014 is an important year for Fibrocell and the first quarter has us off to a strong start,” said David Pernock, chairman and chief executive officer of Fibrocell. “We began enrollment in our two azficel-T label-extension Phase II trials in restrictive burn scarring and vocal cord scarring. We initiated technology transfer with a second-source cell-therapy manufacturer to produce our genetically-modified autologous fibroblasts for recessive dystrophic epidermolysis bullosa (RDEB), and as a potential source for autologous fibroblasts. And, we expanded our strategically important collaboration agreement with Intrexon Corporation (NYSE: XON) to address the rare connective tissue disorder Ehlers-Danlos syndrome hypermobility-type, made possible through our unique technologies.”

For earnings history and earnings-related data on Fibrocell Science (FCSC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Reading (RDI) Tops Q2 EPS by 4c